20 August 2026

To,

BSE Limited	**National Stock Exchange of India Limited**
Corporate Relationship Department	The Listing Department
Phiroze Jeejeebhoy Towers,	Exchange Plaza, Plot No. C/1, G Block,
Dalal Street,	Bandra – Kurla Complex, Bandra (East)
Mumbai – 400 001	Mumbai – 400 051
BSE Scrip Code: **543308**	**NSE Symbol**: **KIMS**

Dear Madam / Sir,

Subject: **Intimation under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 - allotment of 77,02,182 (seventy-seven lakh two thousand one hundred and eighty-two) warrants on a preferential basis by Krishna Institute of Medical Sciences Limited ("Company") to Dr. Abhinay Bollineni (Promoter), Mr. Adwik Bollineni (Promoter) and Bharas Ventures LLP (a Promoter Group entity)**.

Further to the intimation dated 13 June 2026 in relation to the approval of the board of directors of the Company ("**Board**") for the issuance and allotment of 77,02,182 (seventy-seven lakh two thousand one hundred and eighty-two) warrants on a preferential basis by the Company to Dr. Abhinay Bollineni (Promoter), Mr. Adwik Bollineni (Promoter) and Bharas Ventures LLP (a Promoter Group entity) ("**Allottees**") ("**Preferential Issue**"), the intimation dated 11 July 2026 in relation to the details of the voting results of the extraordinary general meeting of the Company held on 9 July 2026 (wherein the shareholders of the Company approved the Preferential Issue with requisite majority) and the in-principle approval in relation to the Preferential Issue provided respectively by the BSE Limited (by way of their letter bearing reference number LOD/PREF/KS/FIP/633/2026-27) and the National Stock Exchange of India Limited (by way of their letter bearing reference number NSE/LIST/55834), we hereby inform that the Company has received in aggregate Rs. 1,499,999,944.50 (Rupees One hundred forty-nine crore ninety-nine lakh ninety-nine thousand nine hundred forty-four rupees and fifty paise*)* from the Allottees for the warrant subscription, which is equivalent to 25% of the issue price of the said Warrants.

Further we wish to inform you that upon receipt of 25 % of the issue price of the said Warrants (i.e., warrant subscription money), the Finance and Investment Committee of the Board has by way of a resolution passed by circulation on 19 August 2026 (Wednesday) at 18:45 hrs (IST), approved the allotment of 77,02,182 (seventy-seven lakh two thousand one hundred and eighty-two) warrants on a preferential basis by the Company to the Allottees (namely Dr. Abhinay Bollineni (Promoter), Mr. Adwik Bollineni (Promoter) and Bharas Ventures LLP (a Promoter Group entity)), in dematerialized form, as set out in the table below:

Krishna Institute of Medical Sciences Limited
D.No.: 1-8-31/1, Minister Road, Secunderabad - 500 003, Telangana, India
Phone: +91 40 4488 5000/4488 5184 | Fax: +91-40-27840980 | kimshospitals.com
CIN: L55101TG1973PLC040558

Sr. No.	Name of the Allottees	Category @	Number of Warrants allotted	Subscription Amount received (25% of Warrants Issue Price) (INR)	Pre-Preferential Issue shareholding and % (assuming 100% conversion of Warrants)	Post-Preferential Issue shareholding and % (assuming 100% conversion of Warrants)
1.	Dr. Abhinay Bollineni	Promoter	32,09,242	624,999,879.50/-	2,36,495 (0.06%)	34,45,737 (0.81%)
2.	Mr. Adwik Bollineni	Promoter	32,09,242	624,999,879.50/-	40,640 (0.01%)	32,49,882 (0.76%)
3.	Bharas Ventures LLP, a limited liability partnership with Dr. Bhaskara Rao Bollineni (being Promoter of the Company) and Ms. Rajyasri Bollineni (being Promoter of the Company) having made the entire capital contribution of Bharas Ventures LLP	Promoter Group	12,83,698	250,000,185.50/-	NIL	12,83,698 (0.30%)
	Total	**-**	**77,02,182**	**1,499,999,944.50/-**	**-**	**-**

	Category	Pre-Preferential Issue shareholding and %*	Post-Preferential Issue shareholding and %&
	Promoter and Promoter Group	32.50%	33.71%

@ *Dr. Abhinay Bollineni and Mr. Adwik Bollineni prior to the completion of the Preferential Issue are Promoters of the Company and will continue to remain Promoters of the Company post the completion of the Preferential Issue. Similarly, Bharas Ventures LLP prior to the completion of the Preferential Issue is a part of the Promoter Group of the Company and will continue to remain part of the Promoter Group of the Company post the completion of the Preferential Issue.*

* *Given the Proposed Allotees form part of the promoter and promoter group of the Company, we have disclosed the pre-preferential issue shareholding and % for the promoter and promoter group of the Company, as publicly available, basis the quarterly shareholding pattern for the quarter ended 30 June 2026.*

& *Given the Allotees form part of the promoter and promoter group of the Company, we have disclosed the post-preferential issue shareholding and % for the promoter and promoter group of the Company, after having assumed that all Warrants, at a conversion ratio of 1:1, will be converted into equity shares by the Allottees within the timelines prescribed under the SEBI ICDR Regulations..*

The Warrants shall be convertible into equity shares of the Company within a period of 18 (Eighteen) months from the date of allotment of the Warrants. The balance i.e., 75% of the issue price of the Warrants shall be payable by the Warrant holders at the time of exercise of the right attached to the Warrants to convert the Warrants and subscribe to equity shares of the Company.

The Company undertakes to make the listing and trading application to the Stock Exchanges for the equity shares to be allotted upon the exercise of the right of conversion of the Warrants into equity shares by the proposed allottees, in accordance with applicable law.

Since the Company has allotted Warrants which are convertible at a later date into equity shares, presently there is no change in the paid-up equity share capital of the Company.

A copy of this disclosure is being uploaded on the website of the Company at https://www.kimshospitals.com/investors/.

Pursuant to Regulation 169(5) of the Securities and Exchange Bord of India (Issue of Capital & Disclosure Requirements) Regulations, 2018 ("**SEBI ICDR Regulations**"), a copy of the certificate issued by S. R. Batliboi & Associates LLP, Chartered Accountants (having Registration Number: 101049W/E300004), Statutory Auditors of the Company, certifying that the Company is in compliance with Regulation 169(4) of the SEBI ICDR Regulations is enclosed as **Annexure-1** to this letter.

Kindly take the same on record.

Thanking you.

Yours faithfully,

For Krishna Institute of Medical Sciences Limited,

NAGAJAYANTHI JUTTUR RAGHAVENDRA DAS

Digitally signed by NAGAJAYANTHI JUTTUR RAGHAVENDRA DAS
Date: 2026.08.20 00:05:18 +05'30'

Nagajayanthi J. R.
Company Secretary & Compliance Officer

Krishna Institute of Medical Sciences Limited
D.No.: 1-8-31/1, Minister Road, Secunderabad - 500 003, Telangana, India
Phone: +91 40 4488 5000/4488 5184 | Fax: +91-40-27840980 | kimshospitals.com
CIN: L55101TG1973PLC040558

S.R. BATLIBOI & ASSOCIATES LLP
Chartered Accountants

THE SKYVIEW 10
18th Floor, "NORTH LOBBY"
Survey No. 83/1, Raidurgam
Hyderabad - 500 032, India
Tel : +91 40 6141 6000

Independent Auditor's Report on the receipt of consideration of specified securities in connection with preferential issue

The Board of Directors
Krishna Institute of Medical Sciences Limited
D. No. 1-8-31/1, Minister's Road, Secunderabad
Hyderabad, Telangana, 500003

Dear Sir/ Madam

1. This report is issued in accordance with the terms of our service scope letter dated June 02, 2026 and master engagement agreement dated June 02, 2026 with Krishna Institute of Medical Sciences Limited (hereinafter the "Company").

2. In connection with the preferential issue of 7,702,182 Convertible Warrants ("the Warrants"), each convertible into, or exchangeable for, one equity share of face value of Rs. 2 each at an issue price of Rs. 779 each, the Company is required to obtain a report from the Statutory Auditors, with regard to receipt of consideration of specified securities in connection with the preferential issue, as required by Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018, as amended (the "ICDR Regulations").

3. The accompanying statement contains details of receipt of consideration against allotment of specified securities (Warrants) as required by Sub para (4) of para 169 of Part VI of chapter V of the ICDR Regulations in respect of the preferential issue (the "Statement"), which we have initialed for identification purposes only.

Managements' Responsibility for the Statement

4. The preparation of the accompanying Statement is the responsibility of the Management of the Company. This responsibility includes designing, implementing and maintaining internal control relevant to the preparation and presentation of the Statement, and applying an appropriate basis of preparation; and making estimates that are reasonable in the circumstances.

5. The Management is also responsible for ensuring:

   a) the consideration of specified securities is received from respective allottee's bank account;
   b) the consideration of specified securities is received from the bank account of the person whose name appears first in the application;
   c) maintenance of relevant records in relation to point (a) and (b) above; and
   d) compliance with the requirements of the ICDR Regulations.

Auditor's Responsibility

6. Pursuant to the requirements of Sub para (5) of para 169 of Part VI of chapter V of the ICDR Regulations, it is our responsibility to provide limited assurance and conclude as to whether the details provided in the Statement is in accordance with Sub para (4) of para 169 of Part VI of chapter V of the ICDR Regulations and the relevant documents thereof are maintained by the Company as on August 19, 2026.

7. The ICDR Regulations applicable to preferential issue of Warrants require many conditions which are to be complied with subsequent to the issue of warrants. This certificate does not cover those conditions.

8. We conducted our examination of the Statement in accordance with the Guidance Note on Reports or Certificates for Special Purposes issued by the Institute of Chartered Accountants of India ("ICAI"). The Guidance Note requires that we comply with the ethical requirements of the Code of Ethics issued by ICAI.

9. We have complied with the relevant applicable requirements of the Standard on Quality Control (SQC) 1, Quality Control for Firms that Perform Audits and Reviews of Historical Financial Information, and Other Assurance and Related Services Engagements.

S.R. BATLIBOI & ASSOCIATES LLP CHARTERED ACCOUNTANTS HYDERABAD

10. A limited assurance engagement includes performing procedures to obtain sufficient appropriate evidence on the applicable criteria mentioned in paragraph 6 above. The procedures performed vary in nature, timing and extent from, and are less extent than for, a reasonable assurance. Consequently, the level of assurance obtained in a limited assurance engagement is substantially lower than the assurance that would have been obtained had we performed a reasonable assurance engagement. Accordingly, we have performed the following procedures in relation to the Statement:

    a) Obtained listing of allottees together with 25% upfront amount received from each applicant from the management.
    b) With respect to 25% upfront money received by the Company, obtained bank statement of the Company for the period June 09, 2026 to August 19, 2026 and traced the name of the person and the amounts appearing in the Statement to the bank statements. We have relied on the information obtained from the management in this regard and have not performed any independent procedures;
    c) With respect to balance 75% money to be received by the Company, obtained listing of allottees together with amount to be received from the applicant from management; and
    d) Conducted relevant management inquiries and obtained necessary representation.

Conclusion

11. Based on our examination as above, and the information, explanations and management representations provided to us, nothing has come to our attention that causes us to believe that the details provided in the Statement are not in accordance with the requirements of sub para (4) of para 169 of Part VI of chapter V of the ICDR Regulations and the relevant documents thereof are not maintained by the Company as on August 19, 2026.

Restriction on Use

12. This report is addressed to and provided to the Board of Directors of the Company solely for the purpose of further submission to the stock exchanges and should not be used by any other person or for any other purpose. Accordingly, we do not accept or assume any liability or any duty of care for any other purpose or to any other person to whom this report is shown or into whose hands it may come without our prior consent in writing. We have no responsibility to update this report for events and circumstances occurring after the date of this report.

S.R. Batliboi & Associates LLP
Chartered Accountants
ICAI Firm Registration Number: 101049W/E300004

Mitesh Parikh

S.R. BATLIBOI & ASSOCIATES LLP
CHARTERED ACCOUNTANTS
HYDERABAD

per Mitesh K Parikh

Partner
Membership Number: 225333
UDIN: 26225333QGKFNQ3582
Place of Signature: Hyderabad
Date: August 19, 2026

KIMS HOSPITALS™

Statement of Funds Received for the Preferential Allotment of share warrants of Krishna Institute of Medical Sciences Limited pursuant to Chapter V of Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018, as amended ("SEBI ICDR Regulations")

1. Krishna Institute of Medical Sciences Limited ('the Company'), has opened "KRISHNA INSTITUTE OF MEDICAL SCIENCES LIMITED A/C" with Kotak Mahindra Bank Limited, 9-1-129/2 Oxford Plaza, Sarojini Devi Road Secunderabad, Account No. 3751153285 for funds received for the Preferential Allotment of share warrants, each convertible into, or exchangeable for, 1 (One) fully paid-up equity share of the Company of face value of ₹ 2/- (Indian Rupees Two) each (**"Warrants"**), in accordance with the SEBI ICDR Regulations.

2. The Company has received an aggregate amount of Rs. 1,499,999,945 only (Rupees One Hundred Forty-nine crore ninety-nine lakh ninety-nine thousand nine hundred and forty-five only) as on August 19, 2026, against the 25% upfront money for preferential allotment from the allottees as mentioned in below table and the said amount was credited to "KRISHNA INSTITUTE OF MEDICAL SCIENCES LIMITED A/C" with Kotak Mahindra Bank Limited, 9-1-129/2 Oxford Plaza, Sarojini Devi Road Secunderabad, Account No. 3751153285.

Sr. No.	Name of the Allottee's("Allottee's")	Number of warrants allotted on 19 August, 2026	25% upfront money received on 19 August, 2026	Balance 75% of allotment money pending to be received
1.	Dr. Abhinay Bollineni	32,09,242	624,999,880	1,874,999,639
2.	Mr. Adwik Bollineni	32,09,242	624,999,880	1,874,999,639
3.	Bharas Ventures LLP	12,83,698	250,000,185	750,000,557
	Total	**77,02,182**	**1,499,999,945**	**4,499,999,835**

3. The copy of the bank statement for "KRISHNA INSTITUTE OF MEDICAL SCIENCES LIMITED A/C" with Kotak Mahindra Bank Limited, 9-1-129/2 Oxford Plaza, Sarojini Devi Road Secunderabad, Account No. 3751153285 as on August 19, 2026, enclosed as Annexure I.

4. The particulars given above are in agreement with books and records of the Company.

For Krishna Institute of Medical Sciences Limited

Name: Sachin Ashok Salvi
Designation: Chief Financial Officer

Place: Hyderabad, India
Date: August 19, 2026

FOR IDENTIFICATION PURPOSES ONLY
S.R. BATLIBOI & ASSOCIATES LLP
HYDERABAD
CHARTERED ACCOUNTANTS

Krishna Institute of Medical Sciences Limited
D.No.: 1-8-31/1, Minister Road, Secunderabad - 500 003, Telangana, India
Phone: +91 40 4488 5000/4488 5184 | Fax: +91-40-27840980 | kimshospitals.com
CIN: L55101TG1973PLC040558